Imagion Biosystems Obtains US$150,000 Non-Dilutive Loan from Executive Chairman Robert Proulx

Imagion Biosystems’ Innovative Cancer Detection and Market Positioning

Imagion Biosystems is advancing clinical-stage medical imaging by developing MagSense®, a first-of-its-kind MRI imaging agent. Utilizing non-radioactive, bio-safe magnetic nanoparticles, the company is enhancing molecular MRI technology to improve diagnostic accuracy across various cancers, including HER2+ breast cancer, prostate, and ovarian cancers. These focus areas represent substantial opportunities within oncology diagnostics, where early and accurate detection significantly influences patient outcomes and treatment success.

Operating from Suite 2, Level 11, 385 Bourke Street, Melbourne, Victoria, Imagion is positioned within Australia’s expanding medtech sector. As a clinical-stage entity, it is progressing its technology toward wider clinical applications and regulatory approvals. The MagSense® platform is the company’s core intellectual property, aiming to empower clinicians with earlier and more precise cancer detection compared to current standard diagnostics. This emphasis on precision medicine and early detection addresses a critical global healthcare need.

Details and Terms of the US$150,000 Loan Facility

The loan agreement with Executive Chairman Robert Proulx provides Imagion Biosystems with access to up to US$150,000 to support working capital. Interest is fixed at 8.0% per annum, applied only to amounts drawn, allowing efficient management of borrowing costs. The loan term is four months from the date of any advance, with repayment due within that period. The facility is unsecured, imposing no liens on company assets and minimizing balance sheet encumbrances.

This flexible draw-down structure enables capital access as operational needs emerge, offering cash flow adaptability during development phases. The short four-month term aligns with bridging finance arrangements to cover near-term operational gaps or initiatives. Calculating interest solely on drawn amounts avoids costs on undrawn funds, making it more efficient than traditional committed facilities. This setup suggests the company anticipates specific funding requirements over the coming months rather than immediate full utilization.

Conversion Rights and Equity Impact Potential

A key feature of the loan is conversion rights, permitting outstanding principal and accrued interest to be converted into fully paid ordinary shares, subject to terms outlined in the Agreement. Conversion is conditional upon satisfying relevant conditions, including shareholder and regulatory approvals, and is not automatic.

This conversion option presents a potential pathway to equity, which could alter the company’s capital structure depending on whether conditions are met. Shareholder and regulatory consents ensure conversion occurs only with explicit approval. Concurrent with this announcement, the company filed an Appendix 3B per ASX Listing Rules, detailing the maximum securities issuable under the conversion mechanism. Further announcements will be made if conversion transpires, ensuring investors remain informed of material capital structure changes.

Board Oversight and Arm’s Length Commercial Terms

Imagion Biosystems’ Board confirmed the loan was negotiated on arm’s length commercial terms and serves the best interests of the company and shareholders. Executive Chairman Robert Proulx recused himself from all related discussions and decisions, ensuring independent board evaluation free from conflicts of interest. This governance approach underscores the company’s commitment to rigorous scrutiny of related-party transactions.

The Board’s arm’s length assessment indicates that the 8.0% interest rate and loan conditions align with market standards for similar unsecured short-term financing. The transparent interest structure and unsecured nature reinforce the commercial fairness of the arrangement. The Board’s explicit endorsement provides shareholders with confidence in the transaction’s rationale and fairness.

Non-Dilutive Financing Strategy

The loan facility is described as "non-dilutive" short-term funding, distinguishing it from equity raises that dilute existing shareholder stakes. For a clinical-stage company like Imagion, maintaining equity ownership is vital as it progresses toward regulatory milestones and commercialization. By opting for debt financing, the company preserves shareholder value and retains flexibility for future capital raises, avoiding immediate dilution unless conversion rights are exercised.

This non-dilutive approach is especially advantageous in market conditions where equity valuations are constrained or equity raises are unfavorable to shareholders. The four-month term suggests a bridging finance solution addressing near-term cash needs. Investors may view this as prudent capital management, minimizing dilution while securing necessary working capital. Conversion rights provide optionality for future equity conversion if strategically appropriate.

Regulatory Compliance and ASX Listing Rules Adherence

Imagion Biosystems complies with ASX Listing Rules concerning the loan facility. The concurrent filing of Appendix 3B discloses the maximum potential securities issuable upon conversion, ensuring market transparency on potential dilution. This disclosure allows investors to evaluate the impact of possible equity issuance.

The company commits to ongoing disclosures, including announcements of any loan conversions, fulfilling continuous disclosure obligations. Shareholder and regulatory approvals required before conversion provide additional safeguards and transparency. Filing Appendix 3B and maintaining open communication demonstrate adherence to ASX and regulatory frameworks governing related-party transactions and equity issuance.

Working Capital Support and Cash Flow Management

The loan is designated to support working capital, reflecting typical cash flow management challenges for clinical-stage medtech companies. Working capital needs include funding research and development, clinical trials, personnel, regulatory affairs, and corporate administration. The flexible draw-down feature allows capital deployment aligned with specific operational requirements, preserving cash runway and minimizing unnecessary interest expenses.

With a four-month term, the company anticipates resolving near-term working capital demands through revenue generation, additional funding, or operational milestones that reduce cash burn. This approach highlights management’s focus on efficient capital use and liquidity maintenance during clinical development.

Clinical Development Phase and Commercialization Outlook

As a clinical-stage company, Imagion Biosystems is conducting or preparing for human clinical trials but has not yet achieved full regulatory approval or commercialization. MagSense® is the lead product candidate, targeting multiple cancer types including HER2+ breast, prostate, and ovarian cancers. This stage is critical for generating safety and efficacy data to support regulatory submissions.

The loan-funded working capital likely supports clinical and regulatory advancement efforts. Investors should recognize the inherent risks and potential rewards of clinical-stage development, including regulatory uncertainties and lengthy timelines. The company’s multi-indication focus aims to diversify commercial opportunities and expand the addressable market for MagSense® technology.

Investor Relations and Communication Channels

Imagion Biosystems maintains robust investor communication through its Investor Hub at investor.imagionbiosystems.com, enabling stakeholders to access updates and engage with company representatives. Contact options include [email protected] and direct phone access to the Executive Chairman, facilitating transparent dialogue.

Media and investor relations are managed by Erich Boileau of Boileau & Co., reflecting professional investor relations support to ensure consistent and accurate market communications. The company’s commitment to timely announcements regarding loan conversions and material developments underscores its dedication to transparency and regulatory compliance.

Risks Associated with Short-Term Debt Financing

While the loan provides immediate working capital relief, the four-month repayment horizon necessitates refinancing or repayment strategies upon maturity. Failure to address working capital needs within this timeframe may require additional capital raises, loan conversion to equity, or alternative financing. Reliance on the Executive Chairman as lender introduces concentration risk dependent on his continued support and financial capacity.

Investors should monitor the company’s progress toward operational milestones and longer-term funding solutions to mitigate refinancing risks. The conversion rights may lead to future dilution, contingent on meeting conversion conditions and obtaining approvals. Understanding these financing dynamics is essential for assessing Imagion Biosystems’ sustainability and growth prospects.